Inhaled Oxytocin

CONDITION ADDRESSED: Postpartum hemorrhage

Treatment
Treatment
  • PREVENTION
  • DIAGNOSTIC
  • TREATMENT

CONTACT INFORMATION

Organization

Monash Institute of Pharmaceutical Sciences (MIPS)

Individual Contact

Michelle McIntosh | Email

Applications

Every year, over 100,000 women die of postpartum haemorrhage (PPH), a condition of excessive blood loss after childbirth. Although PPH can be effectively prevented or treated with an injection of oxytocin, access to this drug is limited due to the requirements for refrigeration, storage and trained medical personnel for administration. A team at Monash Institute of Pharmaceutical Sciences, led by Dr. Michelle McIntosh, is working on a project to develop a novel aerosol delivery system for oxytocin that can be inhaled by patients from a simple, disposable device immediately after childbirth.

Stage of Development

Early R&D

Funding Source

Bill and Melinda Gates Foundation